Hjem › Eggstokkreft › Rhode Island
Kliniske studier for Eggstokkreft i Rhode Island
16 studier for Eggstokkreft søker deltakere på steder i Rhode Island.
Byer i Rhode Island
Offisiell studietekst (engelsk)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05564377A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Women & Infants Hospital /ID# 277930, Providence
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 1. okt. 2026 · NCT07024784TLR9 Immunotherapy for Peritoneal Carcinomatosis
- Rhode Island and the Miriam Hospitals (Brown University Health), Providence
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07658196A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Women & Infants Hospital /ID# 274716, Providence
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT06890338A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Women & Infants Hospital, Providence
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Women & Infants Hospital ( Site 0001), Providence
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 17. sep. 2026 · NCT07318558A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Women & Infants Hospital ( Site 0050), Providence
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 3. sep. 2026 · NCT06824467Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Providence
RekruttererFase 1/2
Alder 18 til 130 · Alle kjønn · Oppdatert 21. aug. 2026 · NCT05797168Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT07001748A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Women and Infants Hospital, Providence
Rekrutterer
Alder 35 til 50 · Kvinner · Oppdatert 7. aug. 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Women and Infants Hospital, Providence
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT05579366A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Lifespan Cancer Institute - Rhode Island Hospital, Providence
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- Women's and Infant's Hospital, Providence
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 50 til 74 · Kvinner · Oppdatert 6. mai 2026 · NCT00539162A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Site 0191, Providence
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 7. apr. 2026 · NCT04516447SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.